Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2b study of PRV-015 in adults with non-responsive celiac disease
2020-000649-16Phase 2Completed
- Sponsor
- Provention Bio
- Start
- Feb 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in celiac disease comparing PRV-015 + gluten-free diet with Placebo + gluten-free diet (2 arms). Primary endpoint: Celiac Disease Patient-Reported Outcome abdominal symptoms. Started Feb 2021; status: completed.
02
Drugs
ordesekimab
03
Conditions
celiac disease
Beyond the preview
Go deeper on 2020-000649-16.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-000649-16.